[hy-DROX-ee-you-ree-ah] Pregnancy Category: D

Hydrea (Abbreviation: HYD) Classification: Antineoplastic, anti-metabolite

See also Antineoplastic Agents. Action/Kinetics: Inhibits DNA synthesis but not synthesis of RNA or protein. As an antimetabolite, it interferes with the conversion of ribo-nucleotides to deoxyribonucleotides due to blockade of the ribonucleotide reductase system. May also inhibit incorporation of thymidine into DNA. Rapidly absorbed from GI tract. Peak serum concentration: 1-2 hr. t1/2: 3-4 hr. Crosses the blood-brain barrier. Degraded in liver; 80% excreted through the urine with 50% unchanged; also excreted as respiratory CO2.

Uses: Chronic, resistant, myelocytic leukemia. Carcinoma of the ovary (recurrent, inoperable, or metastat-ic). Melanoma. With irradiation to treat primary squamous cell carcino


ma of the head and neck (but not the lip). Non-FDA Approved Uses: Sickle cell anemia, thrombocytopenia, HIV, psoriasis.

Contraindications: Leukocyte count less than 2,500/mm3 or thrombocyte count less than 100,000/mm3. Severe anemia. Special Concerns: Use during pregnancy only if benefits clearly outweigh risks. Give with caution to clients with marked renal dysfunction. Geriatric clients may be more sensitive to the effects of hydroxyu-rea necessitating a lower dose. Dosage has not been established in children.

Additional Side Effects: Erythro-cyte abnormalities including mega-loblastic erythropoiesis. Constipation, redness of the face, maculo-papular rash.

How Supplied: Capsule: 500 mg


Was this article helpful?

0 0

Post a comment